or 22.90% over the same period of last year of which hospital revenues totally raised by 10.16% along with the enlarged customer base of Subsidiary (AMARC) showing 15.67% of revenues’ growth. In

by its indirect subsidiary Indorama Netherlands B.V. (“INBV”) of 83,000,000 newly issued shares in Indo Rama Synthetics (India) Limited (“IRSL”), equaling to approximately 31.79% of IRSL’s enlarged

year 2017 was advanced to Baht 193.83 million, a growth of 24.33% over same period of last year which was mainly driven by:-  Growing of 11.87% consolidated revenues over the same period of last year to

consolidated revenues have increased to Baht 360.4 and Baht 797.3 million, a 0.8% and 11.8% growth over same period of last year with details as the followings: - The revenues for 2nd-quarter and 6-month

issued shares in Indo Rama Synthetics (India) Limited (“IRSL”), equaling to approximately 31.79% of IRSL’s enlarged share capital (the “Share Purchase”) at the price of INR 36 per share. The Company would

2019 of Baht 596.1 million, representing a growth of 9.8% from 2018 mainly due to the increase in both revenue from sale of goods and revenue from rental and rendering of services, increased gross profit

had successfully recorded a sales growth of Baht 27.4 million, or 4.1% year-over-year. Please find the details of sales growth by business units as following: - Processing food from meat business

revenues were able to growth better than overall of the industry. 2. Selling and Administrative Expenses Selling and Administrative Expenses increase in accordance with sales. In Q3/2019, the company’s

corresponding period last year, or 36.62% increased, which was better than the average growth rate of industry. These are because of our correct expanding strategy that emphasized on real demand segment, and

corresponding period last year, or 45.30% increased. The increment was in accordance with company’s expanding strategy and management; therefore, company’s revenues were able to growth more than overall of